Update on Trulicity availability in Australia

Eli Lilly Australia (Lilly) anticipates the global supply pressures resulting from increased demand for our Type 2 Diabetes (T2D) medication, Trulicity (dulaglutide), will extend beyond 31 December 2022 and into the foreseeable future.  

Healthcare professionals are asked to consider the impact of limited product availability on patients when making treatment choices, particularly for new patient initiations.  

Lilly is focused on maintaining supplies of Trulicity at levels that will support existing patients already on treatment in Australia. We currently anticipate that patients could experience delays of several weeks in having their prescriptions filled, depending on location and wholesaler.  

Further updates on Trulicity supply status can be found at www.lilly.com.au